JNJ Earnings Date: Jan 20, 2027 (Estimated) — Johnson & Johnson
NYSE · Healthcare · Drug Manufacturers - General
Updated
When is JNJ's next earnings date?
Johnson & Johnson (JNJ) is expected to report Q4 2026 earnings on Wednesday, January 20, 2027 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $2.98 on revenue of $26.48B.
How did JNJ do in its last earnings report?
In its most recent report on Oct 13, 2026 (Q3 2026), Johnson & Johnson posted EPS of $2.59 versus the $2.78 estimate, a miss of 6.8%. Revenue was $25.40B against a $25.36B estimate. The stock's 1-day post-earnings move was -5.7%.
How much does JNJ stock move after earnings?
JNJ beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 2.3% (up or down) in the day after earnings.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
🤖 AI Earnings Analysis
JNJ’s ERLEADA data showed a 62% reduction in recurrence or death, but its latest EPS miss of 6.83% drove shares down 5.7% in one day.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-13 | Q3 2026 | 2.78 | 2.59 | -6.83% | $25.40B | ❌ Miss | -5.73% | -3.77% | — |
| 2026-07-15 | Q2 2026 | 2.85 | 2.90 | +1.75% | $25.31B | ✅ Beat | -2.69% | -1.27% | +2.76% |
| 2026-04-14 | Q1 2026 | 2.67 | 2.70 | +1.12% | $24.06B | ✅ Beat | +0.90% | -3.05% | -5.76% |
| 2026-01-21 | Q4 2025 | 2.47 | 2.46 | -0.40% | $24.56B | ❌ Miss | -0.09% | +2.85% | +13.15% |
| 2025-10-14 | Q3 2025 | 2.76 | 2.80 | +1.45% | $23.99B | ✅ Beat | -0.03% | +1.48% | +1.54% |
| 2025-07-16 | Q2 2025 | 2.67 | 2.77 | +3.75% | $23.74B | ✅ Beat | +6.19% | +8.22% | +12.41% |
| 2025-04-15 | Q1 2025 | 2.60 | 2.77 | +6.54% | $21.89B | ✅ Beat | -0.48% | +2.20% | -5.18% |
| 2025-01-22 | Q4 2024 | 2.02 | 2.04 | +0.99% | $22.52B | ✅ Beat | -1.94% | +1.51% | +8.65% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY26 · $25.40B total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| Innovative Medicine | 66.0% | $16.76B | +7.7% | $13.87B | $15.20B | $15.56B | $15.76B |
| MedTech | 34.0% | $8.64B | +2.5% | $8.02B | $8.54B | $8.43B | $8.80B |
By region
Q3 FY26 · $10.44B total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| Europe | 51.8% | $5.41B | -0.6% | $5.11B | $5.39B | $5.44B | $5.60B |
| Asia-Pacific, Africa | 35.0% | $3.65B | +1.0% | $3.31B | $3.61B | $3.61B | $3.50B |
| Western Hemisphere, excluding U.S. | 13.3% | $1.39B | +12.5% | $1.17B | $1.21B | $1.23B | $1.27B |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.